Abstract: A stable solid pharmaceutical composition for oral administration comprising dapiprazole or a physiologically acceptable acid salt thereof together with a pharmaceutically acceptable inert excipient and magnesium oxide as a degradation retarding agent is disclosed.

Abstract: Treatment of contact lenses by an effective amount of bendazac, 5-hydroxybendazac or a salt thereof with a physiologically acceptable base.

Abstract: Compounds of the formulaA--CH.sub.2 --O--CRR'--COOR'" (I)wherein A, R, R' and R'" have the meanings mentioned in the description, salts thereof with pharmaceutically acceptable bases, intermediates and processes for their preparation, and analgesic pharmaceutical compositions containing them.

Abstract: Method for inhibiting the development of tolerance in the analgesic treatment with morphine of a subject in need of said treatment, comprising administering systemically and contemporarily an effective analgesic dose of morphine and an amount of dapiprazole of from 1/4 to 1 part by weight to 1 part by weight of said analgesic dose of morphine.Pharmaceutical composition useful in the said method.

Abstract: Treatment of contact lenses by an effective amount of bendazac, 5-hydroxybendazac or a salt thereof with a physiologically acceptable base.

Abstract: Treatment of contact lenses by an effective amount of bendazac, 5-hydroxybendazac or a salt thereof with a physiologically acceptable base.

Abstract: It was discovered that bendazac, or (1-phenylmethyl-1H-indazol -3-yl)oxy acetic acid, when administered in a form suitable to obtain therapeutic tissue concentrations, determine an improvement in retinitis pigmentosa. The lysine salt of bendazac is well adapted for this use owing to its good oral absorption.

Abstract: It was discovered that bendazac, or [(1-benzyl-1H-indazol-3-yl)oxy] acetic acid, when administered in a form suitable to obtain therapeutic tissue concentrations, determines a regression of cataract. It was demonstrated in particular, that the lysine salt of bendazac is well adapted for this use since it produces adequate tissue concentrations following both oral administration and topical application on the eye. The chemical and physical characteristics of this bendazac salt are described here together with the preparation techniques.

Abstract: A new salt of [(1-benzyl-1H-indazol-3-yl)oxy] acetic acid (or bendazac) with L. lysine.Following oral administrations of this compound in man, the concentrations of bendazac found in the blood are higher than those obtained after administration of bendazac as such.This discovery extends the therapeutic use of bendazac. In fact, whereas up to now bendazac could only be used topically, the L. lysine salt of bendazac makes it possible to perform therapeutic treatments with the oral route of administration as an agent with a normalizing effect on blood lipids.

Abstract: Compounds of the general formula: ##STR1## in which alk and alk' represent the bivalent radicals: aliphatic alkyl chains; and R and R' represent the alkyl, halogen, hydrogen, alkyloxy, --OH, --CF.sub.3 or --SCH.sub.3 radicals. The compounds of the formula I are effective as antiglaucomic, antipsychotic and also as additive agents in the withdrawal treatment of various addictive conditions. Methods for their preparation are also disclosed.

Abstract: Compounds of the general formula: ##STR1## in which alk and alk' represent the bivalent radicals aliphatic alkyl chains; and R and R' represents the alkyl, halogen, hydrogen, alkyloxy, --OH, --CF.sub.3 or --SCH.sub.3 radicals. The compounds of the formula I are, effective as antiglaucomic, antipsychotic and also as additive agents in the withdrawal treatment of various addictive conditions. Methods for their preparation are also disclosed.

Abstract: This invention relates to the use of substituted 1-benzyl-1H-indazole-3-carboxylic acids to interrupt pregnancy. These compounds are described in the U.S. Pat. No. 3,895,026 assigned to the same assignee of the present patent application.

Abstract: Compound belonging to the class of 2-benzyl-3-(3-dimethylaminopropylthio)-2H-indazole, its sulfoxide and its sulfone and their pharmacologically acceptable salts, and process for obtaining such compounds having an antiinflammatory action in the common pathological conditions.

Abstract: Compounds of the general formula: ##STR1## in which alk and alk' represent the bivalent radicals; aliphatic alkyl chains; and R and R' represent the alkyl, halogen, hydrogen, alkyloxy, --OH, --CF.sub.3 or --SCH.sub.3 radicals. Said compounds of the formula I are effective and useful as antiglaucomic and antipsychotic agents and also as additive agents in the withdrawal treatment of various addictive conditions. Methods for their preparation are also disclosed.

Abstract: Treatment of tremors in Parkinsonism and in other extrapyramidal syndromes by administering an amount of trazodone of the formula ##STR1## AND OR OF ETOPERIDONE OF THE FORMULA: ##STR2## in the range of about 25 mg. to 100 mg. three times a day.

Abstract: A new process by which cyclohexanone is treated, in the presence of a suitable acid or a salt of an organic base, with pyruvic acid or with one of its simple derivatives (ester or salt) to give hydratropic acid.

Abstract: This invention provides guaiacol p-isobutyl hydratropate as a new compound for use in human therapy as an analgesic, anti-inflammatory, antipyretic, antiseptic and expectorating agent.

Abstract: A combination of trazodone or etoperidone with L-DOPA is used in the treatment of Parkinsonism by oral administration to a patient.

Abstract: A process is provided for the production of m-benzoyl-hydratropic acid which comprises heating the reaction mixture obtained from the condensation of 2-benzoyl-cyclohexanone and pyruvic acid, its esters or salts, at a temperature of 200.degree. to 230.degree. and in the presence of an acid catalyst.

Abstract: 4-Acetamidophenyl-p-isobutyl hydratropate having analgesic, anti-inflammatory, antipyretic and antirheumatic activity.